Table 2.
Time to addition of third antihypertensive medication: comparison among angiotensin II receptor blockers
| Fimasartan (n = 928) |
Candesartan (n = 1,541) |
Eprosartan (n = 92) |
Irbesartan (n = 590) |
Losartan (n = 7,390) |
Olmesartan (n = 5,293) |
Telmisartan (n = 7,319) |
Valsartan (n = 11,269) |
P-value | |
|---|---|---|---|---|---|---|---|---|---|
| Third medication addition rate, n (%) | |||||||||
| definition 1 | 58 (6.25) | 372 (24.14) | 29 (31.52) | 186 (31.53) | 1609 (21.77) | 441 (8.33) | 589 (8.05) | 1049 (9.31) | < 0.001 |
| definition 2 | 38 (4.09) | 332 (21.54) | 27 (29.35) | 176 (29.83) | 1507 (20.39) | 308 (5.82) | 462 (6.31) | 745 (6.61) | < 0.001 |
| Time to third medication addition, days | |||||||||
| definition 1 (Median [IQR1 - IQR3]) | 243 (194, 547) | 203 (187, 239.5) | 210 (188, 280) | 194 (184, 218) | 201 (186, 241) | 225 (188, 552) | 238 (193, 538) | 238 (192, 548) | < 0.001 |
| definition 2 (Median [IQR1 - IQR3]) | 213.5 (184, 278) | 198 (186, 218) | 203 (187, 240) | 193 (183, 211) | 198 (186, 231) | 198 (185, 242.5) | 213 (190, 357) | 204 (188, 267) | < 0.001 |
Definition 1: A claim exists for the prescription of CCBs, ARBs, and beta-blockers or diuretics between July 1, 2017, and December 31, 2020
Definition 2: A claim exists for the prescription of CCBs, ARBs, and beta-blockers or diuretics between July 1, 2017, and December 31, 2020, with a consistent ARB since index time, maintained until the third drug claim
Abbreviation: SD, standard deviation; IQR, interquartile